modelAnimals

Extends from Pharmacolibrary.Drugs.ATC.V.V01AA11.

Information

name:Animals
ATC code:V01AA11
route:
compartments:0
dosage:1mg
volume of distribution:1L
clearance:0
other parameters in model implementation

ATC code V01AA11 corresponds to allergens of animal origin used for diagnostic purposes, such as in allergen extracts for skin testing in suspected allergies. These are not conventional drugs but biological extracts derived from animal tissues. Such products are used for identifying allergic sensitivities and are generally not used therapeutically. They are approved and regulated for diagnostic use.

Pharmacokinetics

No published pharmacokinetic (PK) data available for allergens of animal origin classified under ATC code V01AA11. These agents are protein extracts used in very small and variable doses for diagnostic testing, not for systemic pharmacological effect. Thus, conventional PK parameters such as clearance, volume of distribution, bioavailability, and absorption rates are not established or typically reported.

References

  1. Sheiner, LB, & Ludden, TM (1992). Population pharmacokinetics/dynamics. Annual review of pharmacology and toxicology 32 185–209. DOI:10.1146/annurev.pa.32.040192.001153 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1605567

  2. Hurrell, R, & Egli, I (2010). Iron bioavailability and dietary reference values. The American journal of clinical nutrition 91(5) 1461S–1467S. DOI:10.3945/ajcn.2010.28674F PUBMED:https://pubmed.ncbi.nlm.nih.gov/20200263

  3. Keizer, RJ, et al., & Beijnen, JH (2010). Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical pharmacokinetics 49(8) 493–507. DOI:10.2165/11531280-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20608753

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)